Riskified, CoreWeave, Micron And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed; Riskified surged 27.7% on strong Q3 results and raised FY26 guidance. Gevo, Fossil, PepGen and tech stocks also rallied.
Stocks · News reference
PepGen Reports Positive Early-Stage Trial Results for Myotonic Dystrophy Type 1 Treatment
PepGen announced promising clinical trial data for its lead candidate, PGN-EDODM1, showing a 46.5% mean splicing correction in patients with myotonic dystrophy type 1.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Maintains Outperform on PepGen, Raises Price Target to $10
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
PepGen Inc. has initiated a proposed public offering of its common stock to raise $125.0 million.
Wedbush Adjusts PepGen Price Target to $10 From $4
Wedbush has raised its price target for PepGen Inc. to $10 from $4 while maintaining an Outperform rating.
Nasdaq Down Over 200 Points; US Consumer Prices Increase 0.4% In October
U.S. stocks fell as October CPI topped expectations; energy led losses. Oil and gold declined, while European and Asian markets advanced.
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
PepGen Inc. released its financial results for the third quarter of 2026 and provided an update on its corporate progress.